These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 34339865)

  • 21. Real-World Evidence in the Real World: Beyond the FDA.
    Krause JH; Saver RS
    Am J Law Med; 2018 May; 44(2-3):161-179. PubMed ID: 30106647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia.
    Webster J; Smith BD
    Clin Ther; 2019 Feb; 41(2):336-349. PubMed ID: 30709609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world Data and Evidence to support a switch in status from Prescription drug to Over the Counter drug as applied by the EMA, the US FDA, the MHRA, and the BfArM.
    Kühler TC; Ateka A; Lassoued Z; Routhier FX; Mékary-Sawaya S
    Clin Ther; 2024 Mar; 46(3):208-216. PubMed ID: 38278703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contribution of Real-World Evidence in European Medicines Agency's Regulatory Decision Making.
    Bakker E; Plueschke K; Jonker CJ; Kurz X; Starokozhko V; Mol PGM
    Clin Pharmacol Ther; 2023 Jan; 113(1):135-151. PubMed ID: 36254408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design.
    Dagenais S; Russo L; Madsen A; Webster J; Becnel L
    Clin Pharmacol Ther; 2022 Jan; 111(1):77-89. PubMed ID: 34839524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolving Acceptance and Use of RWE for Regulatory Decision Making on the Benefit/Risk Assessment of a Drug in Japan.
    Nishioka K; Makimura T; Ishiguro A; Nonaka T; Yamaguchi M; Uyama Y
    Clin Pharmacol Ther; 2022 Jan; 111(1):35-43. PubMed ID: 34528701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-World Evidence to Support the Registration of a New Osteoporosis Medicinal Product in Europe.
    Davenport C; Gravel P; Wang Y; Williams SA; Wieland A; Mitlak B
    Ther Innov Regul Sci; 2024 May; 58(3):505-518. PubMed ID: 38341388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of Clinical Data Interchange Standards Consortium (CDISC) Standards for Real-world Data: Expert Perspectives From a Qualitative Delphi Survey.
    Facile R; Muhlbradt EE; Gong M; Li Q; Popat V; Pétavy F; Cornet R; Ruan Y; Koide D; Saito TI; Hume S; Rockhold F; Bao W; Dubman S; Jauregui Wurst B
    JMIR Med Inform; 2022 Jan; 10(1):e30363. PubMed ID: 35084343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Role of Real-World Evidence in FDA-Approved New Drug and Biologics License Applications.
    Purpura CA; Garry EM; Honig N; Case A; Rassen JA
    Clin Pharmacol Ther; 2022 Jan; 111(1):135-144. PubMed ID: 34726771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The application of real-world evidence in drug regulatory decision-making].
    Wicherski J; Haenisch B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2024 Feb; 67(2):149-154. PubMed ID: 38214723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. On the use of RWD in support of regulatory submission in drug development.
    Chow SC; Wang P
    J Biopharm Stat; 2024 Oct; 34(6):777-804. PubMed ID: 38501166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Statistical Roadmap for Journey from Real-World Data to Real-World Evidence.
    Fang Y; Wang H; He W
    Ther Innov Regul Sci; 2020 Jul; 54(4):749-757. PubMed ID: 32557297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world evidence to support regulatory submissions: A landscape review and assessment of use cases.
    Alipour-Haris G; Liu X; Acha V; Winterstein AG; Burcu M
    Clin Transl Sci; 2024 Aug; 17(8):e13903. PubMed ID: 39092896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulatory Approval With Real-World Data From Regulatory Science Perspective in Japan.
    Maeda H; Ng DB
    Front Med (Lausanne); 2022; 9():864960. PubMed ID: 35492312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reality check: Real-world evidence to support therapeutic development in hematologic malignancies.
    Derman BA; Belli AJ; Battiwalla M; Hamadani M; Kansagra A; Lazarus HM; Wang CK
    Blood Rev; 2022 May; 53():100913. PubMed ID: 35272867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA.
    Mofid S; Bolislis WR; Kühler TC
    Clin Ther; 2022 Feb; 44(2):306-322. PubMed ID: 35074209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of real-world data and evidence for medical devices: a qualitative study of key informant interviews.
    Polisena J; Jayaraman G
    Int J Technol Assess Health Care; 2020 Dec; 36(6):579-584. PubMed ID: 33161916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
    Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
    Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized Clinical Trial or Real-World Evidence: How Historical Events, Public Demand, and the Resulting Laws and Regulations Shaped the Body of Medical Evidence.
    Mackowiak JI; Mack CD; Irwin DE; Zura R
    J Orthop Trauma; 2021 Mar; 35(Suppl 1):S17-S21. PubMed ID: 33587542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Understanding Use of Real-World Data and Real-World Evidence to Support Regulatory Decisions on Medical Product Effectiveness.
    Mahendraratnam N; Mercon K; Gill M; Benzing L; McClellan MB
    Clin Pharmacol Ther; 2022 Jan; 111(1):150-154. PubMed ID: 33891318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.